4,747 results match your criteria International Journal of Hematology[Journal]


Comparison of minimal residual disease detection in multiple myeloma by SRL 8-color single-tube and EuroFlow 8-color 2-tube multiparameter flow cytometry.

Int J Hematol 2019 Feb 18. Epub 2019 Feb 18.

Department of Hematology/Oncology, Kameda Medical Center, Kamogawa, Japan.

We sought to determine the efficacy of a new, inexpensive, single-tube 8-color multiparameter flow cytometry (MFC) method (SRL-Flow), which is based on the EuroFlow next-generation flow (NGF) (tube 2 only), to assess minimal residual disease (MRD)-negative status. MRD-negative status is considered a treatment milestone in multiple myeloma (MM). We used 45 bone marrow samples from patients with MM, including 11 cases treated with anti-CD38 monoclonal antibody. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12185-019-02615-zDOI Listing
February 2019

Efficacy and safety of tyrosine kinase inhibitors for newly diagnosed chronic-phase chronic myeloid leukemia over a 5-year period: results from the Japanese registry obtained by the New TARGET system.

Int J Hematol 2019 Feb 14. Epub 2019 Feb 14.

National Hospital Organization Nagoya Medical Center, Nagoya, Japan.

We report the results of a multicenter observational study using the New TARGET system, in which the effectiveness and safety of tyrosine kinase inhibitors (TKIs) were evaluated in newly diagnosed chronic-phase chronic myeloid leukemia (CML) patients. A total of 506 patients were enrolled between April 2010 and March 2013. Median age was 56 (range 18-92) years; 35% of patients were females. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12185-019-02613-1DOI Listing
February 2019

Atypical SIFD with novel TRNT1 mutations: a case study on the pathogenesis of B-cell deficiency.

Int J Hematol 2019 Feb 13. Epub 2019 Feb 13.

Department of Pediatrics and Developmental Biology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8510, Japan.

Mutation in the gene encoding tRNA nucleotidyl transferase, CCA-adding 1 (TRNT1), an enzyme essential for the synthesis of the 3'-terminal CCA sequence in tRNA molecules, results in a disorder that features sideroblastic anemia, B-cell immunodeficiency, periodic fever, and developmental delay. Mutations in TRNT1 are also linked to phenotypes including retinitis pigmentosa, cataracts, and cardiomyopathy. To date, it has remained unclear how defective TRNT1 is linked to B-cell deficiency. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s12185-019-02614-0
Publisher Site
http://dx.doi.org/10.1007/s12185-019-02614-0DOI Listing
February 2019
4 Reads

Potential role of activated factor VIII (FVIIIa) in FVIIa/tissue factor-dependent FXa generation in initiation phase of blood coagulation.

Int J Hematol 2019 Feb 13. Epub 2019 Feb 13.

Department of Pediatrics, Nara Medical University, 840 Shijo-cho, 634-8522, Kashihara, Nara, Japan.

Factor VIIa/tissue factor (FVIIa/TF) initiates blood coagulation by promoting FXa generation (extrinsic-Xa). Subsequent generation of intrinsic FXa (intrinsic-Xa) amplifies thrombin formation. Previous studies suggested that FVIIa/TF activates FVIII rapidly in immediate coagulation reactions, and FVIIa/TF/FXa activates FVIII prior to thrombin-dependent feedback. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12185-019-02611-3DOI Listing
February 2019

Feasibility of salvage cord blood transplantation using a fludarabine, melphalan, and low-dose anti-thymocyte globulin conditioning regimen.

Int J Hematol 2019 Feb 8. Epub 2019 Feb 8.

Leukemia Research Center, Saiseikai Maebashi Hospital, Kamishinden-machi, 564-1, Maebashi, Gunma, 371-0821, Japan.

Primary graft failure (PGF) is a lethal complication that occurs early after allogeneic stem cell transplantation (allo-SCT). Cord blood transplantation (CBT) is a potential re-transplantation option. Total body irradiation (TBI) is often incorporated into the pre-salvage CBT conditioning regimen following PGF; however, patients experiencing PGF are not always amenable to TBI, and non-TBI regimens for salvage CBT should be established. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12185-019-02610-4DOI Listing
February 2019
1 Read

Phase II study of FLAGM (fludarabine + high-dose cytarabine + granulocyte colony-stimulating factor + mitoxantrone) for relapsed or refractory acute myeloid leukemia.

Int J Hematol 2019 Feb 6. Epub 2019 Feb 6.

Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Given the poor prognosis of patients with relapsed/refractory acute myeloid leukemia (AML), better therapy is needed. Fludarabine enhances the efficacy of Ara-C (cytarabine) by increasing intracellular Ara-C-triphosphate. The FLAG (fludarabine, high-dose Ara-C, supported with granulocyte colony-stimulating factor) regimen has been tested for use in AML patients by other investigators. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12185-019-02606-0DOI Listing
February 2019
2 Reads

Prognostic values of increased B7 family proteins in haploidentical hematopoietic stem cell transplantation patients with aGVHD.

Int J Hematol 2019 Feb 6. Epub 2019 Feb 6.

Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, The First Affiliated Hospital of Soochow University, 188 Shizi Street, Suzhou, 215006, Jiangsu, People's Republic of China.

It has been reported that B7H1 and B7H3 play a role in graft-versus-host disease (GVHD), the major cause of treatment-related mortality (TRM) in haploidentical hematopoietic stem cell transplantation (haplo-HSCT) patients; however, the prognostic value of these factors has not been defined. We retrospectively collected 64 haplo-HSCT patients in our hospital from 2013 to 2014, as well as 38 HLA-matched-HSCT patients during the same period as the control group. We analyzed B7H1, B7H3, PD1, soluble CD25, ST2 and TNFR1 at 0 day, + 7 days, + 14 days and + 28 days after HSCT. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s12185-019-02605-1
Publisher Site
http://dx.doi.org/10.1007/s12185-019-02605-1DOI Listing
February 2019
5 Reads

Identification of a novel CCDC22 mutation in a patient with severe Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis and aggressive natural killer cell leukemia.

Int J Hematol 2019 Jan 31. Epub 2019 Jan 31.

Department of Hematology/Oncology, Wakayama Medical University, Wakayama, Japan.

Aggressive natural killer cell leukemia (ANKL) is a rare neoplasm characterized by the systemic infiltration of Epstein-Barr virus (EBV)-associated NK cells, and rapidly progressive clinical course. We report the case of a 45-year-old man with intellectual disability who developed ANKL, and describe the identification of a novel genetic mutation of coiled-coil domain-containing 22 (CCDC22). He presented with persistent fever, severe pancytopenia, and hepatosplenomegary. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12185-019-02595-0DOI Listing
January 2019
3 Reads

Deregulated Polycomb functions in myeloproliferative neoplasms.

Int J Hematol 2019 Jan 31. Epub 2019 Jan 31.

Division of Stem Cell and Molecular Medicine, Center for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan.

Polycomb proteins function in the maintenance of gene silencing via post-translational modifications of histones and chromatin compaction. Genetic and biochemical studies have revealed that the repressive function of Polycomb repressive complexes (PRCs) in transcription is counteracted by the activating function of Trithorax-group complexes; this balance fine-tunes the expression of genes critical for development and tissue homeostasis. The function of PRCs is frequently dysregulated in various cancer cells due to altered expression or recurrent somatic mutations in PRC genes. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s12185-019-02600-6
Publisher Site
http://dx.doi.org/10.1007/s12185-019-02600-6DOI Listing
January 2019
2 Reads

Thalidomide maintenance therapy in Japanese myeloma patients: a multicenter, phase II clinical trial (COMET study).

Int J Hematol 2019 Jan 31. Epub 2019 Jan 31.

Department of Hematology/Oncology, Higashi Nagoya National Hospital, Nagoya, Japan.

A prospective, multicenter, phase II study was performed to assess the efficacy and safety of thalidomide maintenance therapy at different doses in Japanese multiple myeloma (MM) patients. This study included 34 patients (median age, 74 years) who were previously treated with not more than three prior therapies and whose response status was evaluated as at least stable disease. They were randomized into Group A (no maintenance; 12 patients), Group B (50 mg thalidomide maintenance; 12 patients), and Group C (100 mg thalidomide maintenance; 10 patients), respectively. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s12185-019-02607-z
Publisher Site
http://dx.doi.org/10.1007/s12185-019-02607-zDOI Listing
January 2019
2 Reads

Hematopoietic stem cell transplantation in children and adolescents with relapsed or refractory B-cell non-Hodgkin lymphoma.

Int J Hematol 2019 Jan 30. Epub 2019 Jan 30.

Department of Pediatrics, Yamagata University School of Medicine, Yamagata, Japan.

We undertook a retrospective study using the national registry data of hematopoietic stem cell transplantation (HSCT) in Japan to investigate the effect of graft source, particularly autologous or allogeneic tissue, on the treatment outcome in patients aged less than 18 years with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL). Survival analysis was conducted on 31 autologous HSCT (auto-HSCT) and 48 allogeneic HSCT (allo-HSCT) recipients between 1990 and 2013. The 5-year survival rates were significantly lower for allo-HSCT compared to auto-HSCT recipients (32% vs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12185-019-02608-yDOI Listing
January 2019
1 Read

JSH Practical Guidelines for Hematological Malignancies, 2018: II. Lymphoma-8. Adult T-cell leukemia-lymphoma.

Int J Hematol 2019 Jan 30. Epub 2019 Jan 30.

Laboratory of Hematoimmunology, School of Health Sciences, Faculty of Medicine, University of the Ryukyus, 207 Uehara, Nishihara-cho, Okinawa, 903-0215, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12185-018-02588-5DOI Listing
January 2019

Prophylaxis and treatment with mycophenolate mofetil in children with graft-versus-host disease undergoing allogeneic hematopoietic stem cell transplantation: a nationwide survey in Japan.

Int J Hematol 2019 Jan 29. Epub 2019 Jan 29.

Department of Hematology and Oncology, Children's Medical Center, Japanese Red Cross Nagoya First Hospital, 3-35 Michishita-cho, Nakamura-ku, Nagoya, 453-8511, Japan.

We investigated the safety and efficacy of mycophenolate mofetil (MMF) in the prevention and treatment of graft-versus-host disease (GVHD) using a nationwide retrospective survey in Japanese children undergoing hematopoietic stem cell transplantation (HSCT). Overall, 141 children undergoing allogeneic HSCT for hematological malignancy (n = 84), non-malignancy (n = 52), and solid tumors (n = 5) were administered MMF orally (median 8 years; range 0-15 years; 89 males and 52 females) during 1995-2011. Donors were primarily unrelated and mismatched related. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12185-019-02601-5DOI Listing
January 2019
1 Read

Discontinuation of L-asparaginase and poor response to prednisolone are associated with poor outcome of ETV6-RUNX1-positive pediatric B-cell precursor acute lymphoblastic leukemia.

Int J Hematol 2019 Jan 28. Epub 2019 Jan 28.

Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.

ETV6-RUNX1-positive B precursor acute lymphoblastic leukemia (B-ALL) is a common subtype of pediatric B-ALL that has shown excellent outcomes in contemporary clinical trials for pediatric B-ALL. Examinations of the possibility of reducing therapeutic intensity may thus be explored. This prospective study examined outcomes in 205 pediatric patients with ETV6-RUNX1-positive B-ALL uniformly treated following the Japan Association of Childhood Leukemia Study Group (JACLS) ALL-02 protocol. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12185-019-02599-wDOI Listing
January 2019
1 Read

Comparison of neutropenia profiles in different treatment protocols for acute myeloid leukemia using the D-index.

Int J Hematol 2019 Jan 25. Epub 2019 Jan 25.

Division of Hematology, Department of Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke, Tochigi, 329-0498, Japan.

Neutropenia is a major risk factor for opportunistic infections in patients with acute myeloid leukemia (AML) who undergo chemotherapy. In the present study, we retrospectively compared the D-index, which reflects both the depth and duration of neutropenia, between two different chemotherapy regimens for AML. Sixty-seven patients with AML were included: 37 received an induction regimen of daunorubicin (DNR) and cytarabine followed by consolidation therapies consisting of standard-dose cytarabine (SDAC) and other antineoplastic agents; the remaining 30 received idarubicin (IDR) and cytarabine as remission induction therapy followed by high-dose cytarabine (HDAC). Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s12185-019-02593-2
Publisher Site
http://dx.doi.org/10.1007/s12185-019-02593-2DOI Listing
January 2019
6 Reads
1.679 Impact Factor

A case of double-refractory multiple myeloma with both the IgH-MMSET fusion protein and the congenital abnormality t(11;22).

Int J Hematol 2019 Jan 24. Epub 2019 Jan 24.

Department of Hematology/Oncology, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa, Japan.

A 67-year-old female was referred to our hospital with a sternal fracture in March 2008. She received a diagnosis of multiple myeloma (MM) BJP-κ type (ISS stage III). G-banding karyotype revealed 46, XX, t(11;22)(q23. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12185-019-02603-3DOI Listing
January 2019

Clinicopathological features of TAFRO syndrome complicated by acquired hemophilia A and development of cardiopulmonary arrest that were successfully treated with VA-ECMO and tocilizumab.

Int J Hematol 2019 Jan 24. Epub 2019 Jan 24.

The Emergency and Critical Care Center, Mie University Hospital, 2-174, Edobashi, Tsu, Mie, 514-8507, Japan.

TAFRO syndrome and acquired hemophilia A (AHA) are rare, life-threatening diseases; however, the relationship between these two diseases is unknown. A 25-year-old man was transferred to our hospital because of bleeding tendency accompanied by multiple organ failure with generalized edema, massive pleural effusion, and ascites. He was diagnosed with AHA. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12185-019-02604-2DOI Listing
January 2019
1 Read

Renal dysfunction and anemia associated with long-term imatinib treatment in patients with chronic myelogenous leukemia.

Int J Hematol 2019 Jan 24. Epub 2019 Jan 24.

Division of Hematology, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.

Knowledge of the toxicity profile of long-term treatment with imatinib is limited. In the present study, we sought to evaluate renal function and hemoglobin levels during long-term imatinib treatment. Eighty-two patients with chronic myelogenous leukemia in chronic phase who had been on imatinib for over 5 years were retrospectively analyzed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12185-019-02596-zDOI Listing
January 2019
5 Reads

Clinical features at transformation in adult T-cell leukemia-lymphoma with smoldering and chronic types.

Int J Hematol 2019 Jan 24. Epub 2019 Jan 24.

Department of Hematology, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan.

Watchful waiting (WW) is among the treatment options indicated for patients with indolent adult T-cell leukemia-lymphoma (ATL). However, we previously showed that the long-term prognosis of patients with smoldering and chronic ATL is often worse than expected, with many undergoing transformation to aggressive ATL. To identify clinical features associated with transformation of smoldering/chronic ATL, we retrospectively analyzed the clinical features of 44 patients (14 smoldering and 30 chronic) who experienced transformation during WW. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12185-019-02602-4DOI Listing
January 2019
1 Read

Effect of antithymocyte globulin on HLA-mismatched unrelated transplantation.

Authors:
Koji Kawamura

Int J Hematol 2019 Jan 24. Epub 2019 Jan 24.

Division of Hematology, Saitama Medical Center, Jichi Medical University, 1-847, Amanuma-cho, Omiya-ku, Saitama-city, Saitama, 330-8503, Japan.

HLA 1-locus-mismatched unrelated donors (1MMUD) are often considered as alternative donors in allogeneic hematopoietic stem-cell transplantation (allo-HCT) when an HLA-matched related or unrelated donor is unavailable. However, HLA mismatch remains a major risk factor for acute and chronic graft-versus-host disease (GVHD). Antithymocyte globulin (ATG) has been used to prevent acute and chronic GVHD, and multiple studies have shown that use of ATG is associated with decreased acute and chronic GVHD, which is associated with improved QOL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12185-019-02597-yDOI Listing
January 2019

Optimal dosage of methotrexate for GVHD prophylaxis in umbilical cord blood transplantation.

Int J Hematol 2019 Jan 24. Epub 2019 Jan 24.

Department of Hematology and Oncology, Konan Kosei Hospital, 137, Omatsubara,Takaya-cho, Konan, 483-8704, Aichi, Japan.

The combination of methotrexate (MTX) and a calcineurin inhibitor is widely used for GVHD prophylaxis in umbilical cord blood transplantation (UCBT). However, the optimal MTX dosage for GVHD prophylaxis in UCBT remains unclear. In the present study, we investigated the impact of MTX dosage on clinical outcomes following UCBT in a single-center retrospective study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12185-019-02598-xDOI Listing
January 2019

Brentuximab vedotin as frontline treatment for HIV-related extracavitary primary effusion lymphoma.

Int J Hematol 2019 Jan 23. Epub 2019 Jan 23.

Department of Malignant Hematology and Cellular Therapy at Memorial Healthcare System, H. Lee Moffitt Cancer Center, 801 N Flamingo Road, Pembroke Pines, 33028, FL, USA.

Primary effusion lymphoma (PEL) is a rare and aggressive herpesvirus-8 (HHV-8) driven B cell non-Hodgkin's lymphoma (NHL) that is usually associated with human immunodeficiency virus (HIV) infection, and has a poor prognosis. PEL is comprised of two clinically distinct but pathologically similar variants: classic and extracavitary PEL. Based on retrospective series, treatment options include combined antiretroviral therapy (cART) in conjunction with chemotherapy regimens used in other forms of NHLs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12185-019-02592-3DOI Listing
January 2019

JSH practical guidelines for hematological malignancies, 2018: 7. Peripheral T-cell lymphoma (PTCL).

Int J Hematol 2019 Feb 22;109(2):137-140. Epub 2019 Jan 22.

Shimane University Hospital Innovative Cancer Center, 89-1 Enya-cho, Izumo, Shimane, 693-8501, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12185-018-02589-4DOI Listing
February 2019

Hematopoietic stem cell transplantation in primary central nervous system lymphoma: a review of the literature.

Int J Hematol 2019 Jan 22. Epub 2019 Jan 22.

Hematological Malignancies/Stem Cell Transplantation Unit, Division of Hematology/Oncology, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, 10833 Le Conte Ave, Room 42-121 CHS, Los Angeles, CA, 90095, USA.

Primary central nervous system lymphoma (PCNSL) is an uncommon variant of extranodal non-Hodgkin lymphoma (NHL) with an aggressive course and worse outcomes compared with other lymphomas of similar tumor burden and histologic subtype. High-dose chemotherapy supported by autologous stem cell transplantation (HDC/ASCT) is an option for therapy for this disease in both the relapse setting and as post-remission consolidation. Data are currently limited to only several single-arm phase II trials with small sample sizes, but randomized trials are now ongoing. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s12185-019-02594-1
Publisher Site
http://dx.doi.org/10.1007/s12185-019-02594-1DOI Listing
January 2019
5 Reads

Vitamin C deficiency: rare cause of severe anemia with hemolysis.

Int J Hematol 2019 Jan 22. Epub 2019 Jan 22.

Department of Hematology-Oncology, Allegheny Health Network, Pittsburgh, PA, USA.

Historically known to be a disease of sailors and soldiers in the seventeenth and eighteenth century, scurvy is a rare nutritional deficiency in the developed world, but it can still be seen among the alcoholics and the malnourished. We present a case of a 39-year-old alcoholic male who presented with progressive fatigue and diffuse purpuric rash with scattered ecchymosis for 2 months. Blood work was remarkable for hemoglobin of 9. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12185-018-02575-wDOI Listing
January 2019
1 Read

A case of pancytopenia and hypercellular bone marrow: when family history can suggest the diagnosis.

Int J Hematol 2019 Jan 21. Epub 2019 Jan 21.

Department of Pediatrics, Infermi Hospital Rimini, Viale Settembrini 2, 47923, Rimini, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12185-018-02569-8DOI Listing
January 2019

Association of high levels of plasma OX40 with acute adult T-cell leukemia.

Int J Hematol 2019 Jan 16. Epub 2019 Jan 16.

Laboratory of Hematoimmunology, School of Health Sciences, Faculty of Medicine, University of the Ryukyus, Okinawa, Japan.

OX40, a member of the tumor necrosis factor receptor (TNFR) superfamily, co-stimulates activated T cells following interaction with its own ligand OX40L. Human T-cell leukemia virus type-1 (HTLV-1) is an etiological agent of adult T-cell leukemia (ATL). ATL cells are known to express cell surface OX40; however, the level of soluble OX40 (sOX40) in blood samples from ATL patients is unknown. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s12185-018-02580-z
Publisher Site
http://dx.doi.org/10.1007/s12185-018-02580-zDOI Listing
January 2019
4 Reads

New insights into the biology of acute myeloid leukemia with mutated NPM1.

Int J Hematol 2019 Jan 10. Epub 2019 Jan 10.

The Stem Cells and Regenerative Medicine Center, Baylor College of Medicine, Houston, TX, 77030, USA.

Acute myeloid leukemia (AML), the most common acute leukemia in adults, increases exponentially with age. While a number of recent advances have improved treatment, high cure rates have not yet been achieved. Nucleophosmin (NPM1) is found mutated in nearly one-third of newly diagnosed cases and leads to NPM1 protein that is mislocalized to the cytoplasm instead of the nucleolus. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s12185-018-02578-7
Publisher Site
http://dx.doi.org/10.1007/s12185-018-02578-7DOI Listing
January 2019
5 Reads

Prominence of nestin-expressing Schwann cells in bone marrow of patients with myelodysplastic syndromes with severe fibrosis.

Int J Hematol 2019 Jan 10. Epub 2019 Jan 10.

Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Ibaraki, Japan.

Nestin-expressing stromal cells (NESCs) and Schwann cells in the bone marrow (BM) play crucial roles as a niche for normal hematopoietic stem cells in mice. It has been reported that both types of cells are decreased in myeloproliferative neoplasms in patients and also in a mouse model, whereas an increase in NESCs was reported in acute myeloid leukemia. It is thus of interest whether and how these BM stromal cells are structured in myelodysplastic syndromes (MDS). Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s12185-018-02576-9
Publisher Site
http://dx.doi.org/10.1007/s12185-018-02576-9DOI Listing
January 2019
7 Reads

Correction to: Neuronopathic Gaucher disease presenting with microcytic hypochromic anemia.

Int J Hematol 2019 Jan 10. Epub 2019 Jan 10.

Department of Pediatrics, Yeungnam University College of Medicine, Daegu, Republic of Korea.

In the original publication of this article, Fig. 2 was published incorrectly. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s12185-018-02590-x
Publisher Site
http://dx.doi.org/10.1007/s12185-018-02590-xDOI Listing
January 2019
1 Read

Tuberculous lymphadenitis mimicking Castleman disease-like histological features.

Int J Hematol 2019 Jan 10. Epub 2019 Jan 10.

Department of Pathology, Takamatsu Red Cross Hospital, 4-1-3 Ban-cho, Takamatsu, Kagawa, 760-0017, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12185-018-02579-6DOI Listing
January 2019

Immunosuppressive therapy with rabbit antithymocyte globulin therapy for acquired aplastic anemia: a multi-institutional retrospective study in Japanese adult patients.

Int J Hematol 2019 Jan 9. Epub 2019 Jan 9.

Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kamigyo-ku, Kyoto, 602-8566, Japan.

We retrospectively analyzed efficacy and safety of therapy with rabbit antithymocyte globulin (rATG) in combination with cyclosporine A (CsA) in 30 Japanese adult patients with acquired aplastic anemia (AA) in the Kyoto Clinical Hematology Study Group. The median observation period was 31 months and the median age of the patients was 54 years. The objective response rates (ORRs) to rATG plus CsA increased over time until 18 months after the start of treatment; the rate of achievement of better than partial response at 18 months was 66. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s12185-018-02583-w
Publisher Site
http://dx.doi.org/10.1007/s12185-018-02583-wDOI Listing
January 2019
4 Reads

Limited efficacy of high-dose methotrexate in patients with neurolymphomatosis.

Int J Hematol 2019 Jan 3. Epub 2019 Jan 3.

Division of Hematology/Oncology, Department of Medicine, Kameda Medical Center, 929 Higashi-chou, Kamogawa, Chiba, 296-8602, Japan.

Neurolymphomatosis (NL) is a rare manifestation of non-Hodgkin lymphoma, in which malignant cells infiltrate the peripheral nerves. Most patients are treated with high-dose methotrexate (HD-MTX)-based systemic chemotherapy regimens similar to patients with central nervous system lymphoma. However, because NL is rare, the efficacy of HD-MTX is largely unknown. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12185-018-02586-7DOI Listing
January 2019
3 Reads

Clinical features of dyskeratosis congenita in mainland China: case reports and literature review.

Int J Hematol 2019 Jan 3. Epub 2019 Jan 3.

Department of Pediatrics, Tongji Hospital, Tongji University School of Medicine, Xincun Road 389, Shanghai, 200065, People's Republic of China.

Dyskeratosis congenita (DC) is a rare-inherited bone marrow failure syndrome associated with multi-system disorder. To summarize the clinical features, epidemiology, and treatment of DC in mainland China, we retrospectively reviewed the medical records of two patients diagnosed with DC at our hospital and published reports on other DC patients in mainland China. The clinical features of 82 DC patients were summarized. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12185-018-02582-xDOI Listing
January 2019
3 Reads
1.679 Impact Factor

Relationship between clinical course of nivolumab-related myositis and immune status in a patient with Hodgkin's lymphoma after allogeneic hematopoietic stem cell transplantation.

Int J Hematol 2019 Jan 3. Epub 2019 Jan 3.

Department of Hematology, Nephrology and Rheumatology, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita, 010-8543, Japan.

Although programmed cell death (PD)-1 blockade induces immune-related adverse events (irAEs), little is known about the safety of PD-1 blockade after allogeneic hematopoietic stem cell transplantation (HSCT). Here, we describe immune system changes during nivolumab-related myositis in a patient with Hodgkin's lymphoma after allogeneic HSCT; to our knowledge, this is the first such report in the literature. At the onset of myositis, the patient lost lower limb mobility against gravity, and had an activated immune profile with increased cytotoxic CD107a and granzyme B expression, as well as pro-inflammatory cytokines, interferon-γ, tumor necrosis factor-α, interleukin-2 in T and NK cells compared to healthy donor. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12185-018-02584-9DOI Listing
January 2019

Is clinicopathological distinction of mucosa-associated lymphoid tissue lymphoma from Waldenström macroglobulinemia essential in MYD88 L265P mutation-positive cases?

Int J Hematol 2019 Jan 3. Epub 2019 Jan 3.

Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga, 849-8501, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12185-018-02585-8DOI Listing
January 2019
1 Read

Decline of forced expiratory volume in 1 s after allogeneic hematopoietic cell transplantation is a good indicator for pulmonary damage and is associated with busulfan use.

Int J Hematol 2019 Jan 2. Epub 2019 Jan 2.

Department of Hematology and Oncology, JA Aichi Konan Kosei Hospital, 137, Omatsubara, Takaya-cho, Konan, Aichi, 483-8704, Japan.

Reduced pulmonary function is commonly observed after allogeneic hematopoietic stem cell transplantation (HSCT); however, its relationship with the development of noninfectious pulmonary complications (NIPCs) is unclear, and the impact of changes in pulmonary function test (PFT) values on HSCT outcome remains controversial. We conducted a retrospective study including 150 patients to investigate changes in PFTs and impact on clinical outcome. PFT data at around 1 year after HSCT were available in 84 patients, and showed a significant time-dependent decline in percentage predicted forced expiratory volume in 1 s and other parameters. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12185-018-02581-yDOI Listing
January 2019

A case of AITL complicated by EBV-positive B cell and monoclonal plasma cell proliferation and effectively treated with lenalidomide.

Int J Hematol 2019 Jan 2. Epub 2019 Jan 2.

Department of Hematology, Tazuke Kofukai Medical Research Institute, Kitano Hospital, 2-4-20 Ohgimachi, Kita-ku, Osaka, 530-8480, Japan.

Angioimmunoblastic T-cell lymphoma (AITL) is a common subtype of peripheral T-cell lymphoma with an aggressive clinical course and poor prognosis after conventional chemotherapy, for which there is no current standard of care. We describe here an 87-year-old woman with AITL, whose clinical diagnosis was complicated by the presence of B immunoblasts positive for Epstein-Barr virus in the lymph nodes and monoclonal plasma cells in the bone marrow at initial presentation. Rebiopsy of the lymph node led to the correct diagnosis of AITL with concurrent smoldering plasma cell myeloma. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s12185-018-02587-6
Publisher Site
http://dx.doi.org/10.1007/s12185-018-02587-6DOI Listing
January 2019
2 Reads

Inhibitor development, safety and efficacy of Advate among previously treated patients with hemophilia A in a postmarketing surveillance in Japan.

Int J Hematol 2019 Jan 2. Epub 2019 Jan 2.

Kitakyushu Yahata-Higashi Hospital, Kitakyusyu, Japan.

Rurioctocog alfa (recombinant factor VIII: Advate) is available for the control of bleeding in patients with hemophilia A in Japan. To evaluate the inhibitor development, safety, and efficacy of rurioctocog alfa, a non-interventional and observational postmarketing surveillance was conducted on 352 previously treated Japanese patients aged 1-76 years with ≥ 4 exposure days under the conditions of routine clinical practice. A post-hoc comparison of the mean annualized bleeding rates which required treatment with rurioctocog alfa detected a statistically significant difference (P < 0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12185-018-02574-xDOI Listing
January 2019
2 Reads

Correction to: Inhibitor development, safety, and efficacy of Advate® in previously untreated patients with hemophilia A in a postmarketing surveillance in Japan.

Int J Hematol 2019 Feb;109(2):241

Kitakyushu Yahatahigashi Hospital, Kitakyusyu, Japan.

The authors would like to correct the errors in the publication of the original article. The correction details are given below. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12185-018-02564-zDOI Listing
February 2019
1 Read

Hematopoietic stem cell transplantation for subcutaneous panniculitis-like T-cell lymphoma: single center experience in an Asian population.

Int J Hematol 2019 Feb 13;109(2):187-196. Epub 2018 Dec 13.

Division of Hematology, Department of Medicine, Taipei Veterans General Hospital, No. 201, Sec 2, Shih-Pai Road, Taipei, 112, Taiwan.

Subcutaneous panniculitis-like T-cell lymphoma (SPTL) is a rare form of cytotoxic T-cell lymphoma. It is believed that SPTL in patients without hemophagocytic syndrome (HPS) follows an indolent course; in contrast, SPTL in patients with HPS has been associated with unfavorable survival. To provide more clinical data on SPTL in Asian populations and to identify optimal therapeutic strategies for SPTL, we assessed the clinicopathological features and long-term follow-up data of 10 Taiwanese SPTL patients diagnosed at a single center. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12185-018-02568-9DOI Listing
February 2019
3 Reads
1.679 Impact Factor

Lead poisoning as final diagnosis in a study of normocytic anemia.

Int J Hematol 2019 Feb 6;109(2):135-136. Epub 2018 Dec 6.

Emergency Service, Miguel Servet University Hospital, Paseo Isabel la Católica 1-3, 50009, Zaragoza, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12185-018-02570-1DOI Listing
February 2019

Comparison of gabexate mesilate and nafamostat mesilate for disseminated intravascular coagulation associated with hematological malignancies.

Int J Hematol 2019 Feb 8;109(2):141-146. Epub 2018 Dec 8.

Division of Hematology, Department of Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke, Tochigi, 329-0498, Japan.

We evaluated clinical outcomes of disseminated intravascular coagulation (DIC) in patients with hematological malignancies treated with synthetic protease inhibitors (SPIs) and compared the effects of gabexate mesilate (FOY) and nafamostat mesilate (FUT). We retrospectively examined 127 patients [acute myeloid leukemia (n = 48), acute lymphoblastic leukemia (n = 25), and non-Hodgkin lymphoma (n = 54)] with DIC, who were diagnosed according to Japanese Ministry of Health, Labour and Welfare criteria and treated with SPIs [FOY (n = 55) and FUT (n = 72)] at our hospital from 2006 to 2015. The DIC resolution rates on days 7 and 14 were 42. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12185-018-02567-wDOI Listing
February 2019
8 Reads
1.679 Impact Factor

Outcomes in children with hemophagocytic lymphohistiocytosis treated using HLH-2004 protocol in Japan.

Int J Hematol 2019 Feb 7;109(2):206-213. Epub 2018 Dec 7.

Department of Pediatrics, Ehime University Graduate School of Medicine, Toon, Japan.

Recent advances in intensive chemo- and immunotherapy have contributed to the outcome of hemophagocytic lymphohistiocytosis (HLH); however, the prognosis of HLH in children differs by HLH subtype. In Japan, secondary HLH, particularly Epstein-Barr virus-associated HLH (EBV-HLH), is the most common HLH subtype. The prognosis of HLH has improved in recent years. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12185-018-02572-zDOI Listing
February 2019

The world's first clinical trial for an aplastic anemia patient with thrombocytopenia administering platelets generated from autologous iPS cells.

Int J Hematol 2019 Feb 7;109(2):239-240. Epub 2018 Dec 7.

Department of Bioethics and Humanities, University of Washington School of Medicine, Seattle, WA, 98195-7120, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12185-018-02565-yDOI Listing
February 2019
1 Read

Complete remission of pure white cell aplasia associated with thymoma after thymectomy and cyclosporine administration.

Int J Hematol 2018 Dec 9. Epub 2018 Dec 9.

Department of Haematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Atomic Disease Institute, Nagasaki University, 1-12-4 Sakamoto, Nagasaki, 852-8523, Japan.

We present the case of a 63-year-old male with pure white cell aplasia (PWCA), a rare complication of thymoma, who was successfully treated with cyclosporine A (CyA) and thymectomy. The patient presented with high fever and agranulocytosis. Complete blood count revealed a white blood cell count of 0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12185-018-02573-yDOI Listing
December 2018
1 Read

Villous lymphocytes in splenic large B-cell lymphoma with diffuse red pulp infiltration.

Int J Hematol 2019 Feb 5;109(2):133-134. Epub 2018 Dec 5.

Department of Pathology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12185-018-02566-xDOI Listing
February 2019
2 Reads

Neutropenic enterocolitis in patients with FLT3 mutated acute myeloid leukemia undergoing induction chemotherapy with midostaurin.

Int J Hematol 2018 Dec 3. Epub 2018 Dec 3.

Department of Hematology and Oncology, Marshall University, 1400 Hal Greer Blvd, Huntington, WV, 25701, USA.

Neutropenic enterocolitis mostly affects patients with acute myeloid leukemia (AML) who get treated with intensive chemotherapy which is associated with prolonged neutropenia; its pathogenesis is not well understood and the main factors in this life-threatening condition appear to be neutropenia, mucosal injury and a weakened immune system as a consequence of intensive chemotherapeutic agents. Midostaurin in combination with chemotherapy became the standard of care for FLT3 mutant AML since its approval by the United States Food and Drug Administration (FDA) in April 2017. Anecdotally in our institution, we noticed the common occurrence of neutropenic colitis in three out of three patients who were treated with midostaurin as part of induction chemotherapy for AML. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12185-018-2558-4DOI Listing
December 2018
1 Read

Aberrant histone modifications induced by mutant ASXL1 in myeloid neoplasms.

Int J Hematol 2018 Dec 5. Epub 2018 Dec 5.

Division of Cellular Therapy, Advanced Clinical Research Center, Division of Stem Cell Signaling, Center for Stem Cell Biology and Regenerative Medicine, Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo, 1088639, Japan.

An epigenetic modulator Additional sex combs-like 1 (ASXL1) is recurrently mutated in myeloid neoplasms such as myelodysplastic syndromes (MDS), acute myeloid leukemia (AML) and myeloproliferative neoplasms (MPNs). ASXL1 mutations are also frequently detected in clonal hematopoiesis with indeterminate potential (CHIP), which is the clonal expansion of premalignant hematopoietic cells without any evidence of hematological malignancies. Thus, understanding the roles of ASXL1 in hematopoiesis and myeloid neoplasms is a clinically crucial issue. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12185-018-2563-7DOI Listing
December 2018
1 Read